Ethics and Drug Resistance: Collective Responsibility for Global Public Health

lt;p>Doctor Euzebiusz Jamrozik is a practising physician and bioethics PhD candidate in the Monash Bioethics Centre at Monash University, where he also completed an MA in Bioethics after prior studies in medicine and philosophy at University of Western Australia. His multidisciplinary interests include infectious disease, public health ethics, and epidemiology. Among other topics, his recent publications focus on ethical implications of vaccination, vector-borne disease, human challenge studies, and climate change impact on infectious disease. He is a Fellow of the Royal Australasian College of Physicians (FRACP) and Member of the World Health Organization (WHO) Collaborating Centre for Bioethics at Monash University.

Professor Michael Selgelid is Director of the Monash Bioethics Centre and the World Health Organization (WHO) Collaborating Centre for Bioethics at Monash University in Melbourne, Australia.  His research primarily focuses on public health ethics, infectious disease ethics, research ethics, and ethical issues associated with biotechnology and other emerging technologies.  He edits a book series in Public Health Ethics Analysis for Springer and is Co-Editor of Monash Bioethics Review.  Michael earned a BS in Biomedical Engineering from Duke University and a PhD in Philosophy from the University of California, San Diego.

Introduction.- Part 1 Theoretical and conceptual approaches to ethics in antimicrobial resistance.- Chapter 1 The practical ethics of antimicrobial resistance as a collective action problem (Julian Savulescu).- Chapter 2 Collective responsibility for antimicrobial resistance (Angus Dawson).- Chapter 3 Moral aspects of antimicrobial stewardship (Marcel Verweij).- Chapter 4 Ethical frameworks for rational antibiotic use (Annette Rid, Jasper Littmann, Alena Buyx).- Chapter 5 The virtuous physician as antimicrobial prescriber (Justin Oakley).- Chapter 6 Solidarity and compliance with antimicrobial policy (Søren Holm, Thomas Ploug).- Chapter 7 Resistance, inequality, and epidemiological transition (Lynette Reid).- Chapter 8 The price of precaution (Joakim Larsson, Christian Munthe).- Part 2 Ethics and antimicrobial resistance in context.- Chapter 9 Hospital acquired infection (Lyn Gilbert & Ian Kerridge).- Chapter 10 Antibiotic use in childhood (Michael Millar).- Chapter 11 Ethics, animals, public goods (Jonny Anomaly).- Chapter 12 Malaria (PY Cheah& Mike Parker).- Chapter 13 Resistant HIV (Bridget Haire).- Chapter 14 Access & availability of new TB drugs (Diego Silva, Adrian Viens, Jasper Littmann).- Chapter 15 TB Resistance and Human rights (Leslie London).- Chapter 16 TB Resistance in developing countries (Richard Coker, Marco Liverani, Mishal Khan).- Chapter 17 Animal Epidemiology (Lisa Boden & Dominic Mellor).- Part 3 Ethical, legal and economic aspects of antimicrobial resistance.- Chapter 18 Privacy and  data collection(Leslie Francis).- Chapter 19 Mandatory treatment  interventions (Carl Coleman).- Chapter 20 Ethics and AMR Regulation (Belinda Bennett).- Chapter 21 Ethics of Drug Development (Nick King).- Chapter 22 Economics of resistance (Coast/Smith).- Conclusion.